Lilly and MiNA Therapeutics Announce saRNA Research Collaboration
News provided by
Share this article
MiNA Therapeutics Logo
INDIANAPOLIS and LONDON, May 11, 2021 /PRNewswire/ Eli Lilly and Company (NYSE: LLY) and MiNA Therapeutics Limited, a pioneer in RNA activation therapeutics, today announced a global research collaboration to develop novel drug candidates using MiNA s proprietary small activating RNA (saRNA) technology platform.
Under the terms of the agreement, MiNA will utilize its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly s key therapeutic focus areas. Lilly will be responsible for preclinical and clinical development of candidates and will retain exclusive commercialization rights for any products resulting from the collaboration. MiNA will receive a $25 million upfront payment and is eligible to receive potential development and commercialization milestones up to a total of $245 million per target, as
Immunicum AB
Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 at the 18th Cancer Immunotherapy Annual Meeting
Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 at the 18th Cancer Immunotherapy Annual Meeting
Press Release
03 May 2021
Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 at the 18th Cancer Immunotherapy Annual Meeting
Immunicum AB (publ; IMMU.ST) announced today the publication of two abstracts for oral presentations covering preclinical data on its lead programs, ilixadencel and DCP-001, at the 18
th Cancer Immunotherapy (CIMT) Annual Meeting, held virtually from Monday, May 10 to Wednesday, May 12, 2021. The accepted abstracts are now available on the conference website. The presentations cover updated preclinical data on the combination of ilixadencel with a checkpoint inhibitor targeting CTLA4 and new preclinical data on the mechanism of action of DCP-001 and its combination with the emerging immunotherapy t
Immunicum Announces Presentations at Upcoming Scientific Conferences in April and May streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Immunicum AB (publ) Initiates Research Collaboration with Icahn School of Medicine at Mount Sinai
Immunicum AB (publ) Initiates Research Collaboration with Icahn School of Medicine at Mount Sinai
Immunicum AB (publ; IMMU.ST) announced today the initiation of a research collaboration with the laboratory of Nina Bhardwaj, M.D., Ph.D., Director of Immunotherapy and the Medical Director of the Vaccine and Cell Therapy Core Facility, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York City.
Dr. Bhardwaj is a leading researcher who has made significant contributions to the field of human dendritic cells and specifically their mode of action. Her translational research has resulted in the development of receptor agonist- and dendritic cell-based vaccines for the treatment of both cancer and infectious diseases, and she has pioneered neoantigen vaccine studies at The Tisch Cancer Institute.
Immunicum AB (publ) Plans to Expand its Research and Process Development Facilities in Leiden, the Netherlands
27 January 2021
Immunicum AB (publ) Plans to Expand its Research and Process Development Facilities in Leiden, the Netherlands
Immunicum AB (publ; IMMU.ST) announced today that its in-house research and process development activities will move into a new facility at the Leiden Bio Science Park, the Netherlands. The Company has signed a long-term lease with developer Kadans Science Partner for approximately 1,100 square meters of laboratory and office space in the Plus Ultra Leiden, a new building currently under development. Furthermore, Immunicum has the option to rent an additional 1,100 square meters to further support its future growth. The new location, that is expected to be fully commissioned in 2022, will serve as Immunicum s core research and development hub.